Our results suggested that the combined use of NP and DX could be a promising therapeutic strategy for targeting the Jak2/Stat3 pathway in neuroblastoma, offering a potential avenue for enhancing effective treatment and overcoming resistance to conventional therapies. The gene discussed is STAT3; the disease is neuroblastoma.